Haleon: 2024 results prompt profit-taking

(CercleFinance.com) - On Thursday, Haleon reported 2024 results that are in line with expectations, with an unsurprising outlook for 2025, although this caused its share price to fall on the London Stock Exchange.


The owner of Sensodyne toothpaste, Voltaren gel and Advil painkiller, said it recorded organic sales growth of 5% last year, including 6.8% in Q4.

The group, which was spun off from British laboratory GSK in 2022, said the price effect was 3.7%, while volumes rose by 1.3%.

Reported 2024 sales were down 0.6%.

For 2025, Haleon forecast annual organic sales growth of between 4% and 6%, in line with its long-term forecasts and analysts' expectations.

Despite this solid publication, the share price lost almost 3% on the London Stock Exchange on Thursday, suffering one of the biggest falls on the FTSE 100 index, a victim of profit-taking, after rising by over 10% over the last three months.


Copyright (c) 2025 CercleFinance.com. All rights reserved.